Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT01355484 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

321

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle Wasting
Non Small Cell Lung Cancer

Interventions

DRUG: GTx-024
DRUG: placebo

Sponsor

GTx